Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-10-23-Speech-2-553-750"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20121023.45.2-553-750"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"I opposed the ACAA agreement as it is inappropriate until there is tangible progress in Israel’s respect for international humanitarian and rights law. Approving ACAA, moreover, is inconsistent with Parliament’s frequently repeated condemnation of Israel’s occupation policies in Gaza and the West Bank. Why should Israel gain increased access to European pharmaceutical markets, without any new, concrete undertakings to meet demands for human rights obligations? EU Trade Commissioner Karel De Gucht told MEPs that the EU does not recognise Israel’s sovereignty over the Occupied Territories and as such will ensure that products under this agreement come only from Israel – not occupied settlements. I sincerely hope that this will be the case. The problem is to ensure that this actually happens on the ground Finally, I wish to express my disappointment at the result of the vote, which unfortunately sends a signal that EU-Israeli cooperation can continue apace regardless of Israel’s policies in the occupied Palestinian territory, which are not recognised by international law. As noted by Irish NGO Trócaire, granting greater access to the Israeli pharmaceutical industry also means benefiting a sector which profits directly from occupation-related policies, as outlined by the Israeli Coalition of Women for Peace."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples